Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synaptic dysfunction-related gene expression spatially correlates with widespread cortical network atrophy in temporal lobe epilepsy.

Neurobiology of disease·2026
Same author

Effect and mechanism of lateralization of cerebellar-cerebral network abnormalities on language in patients with unilateral temporal lobe epilepsy.

Neurological research·2026
Same author

A cross-sectional and longitudinal study of changes in complex networks related to brain function in temporal lobe epilepsy patients treated with levetiracetam intervention therapy.

Brain imaging and behavior·2026
Same author

Persistent white matter disruption underlies apparent functional normalization in intractable temporal lobe epilepsy: Evidence from multimodal MRI.

IBRO neuroscience reports·2026
Same author

Revealing brain network hierarchy and molecular correlates in temporal lobe epilepsy: A multimodal neuroimaging study.

Neurobiology of disease·2026
Same author

Effectiveness of low-dose perampanel in focal epilepsy patients aged twelve or older in Southern China: an observational study.

Scientific reports·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Pregabalin monotherapy for epilepsy.

Qin Zhou1, Jinou Zheng, Lu Yu

  • 1Department of Neurology, First Affiliated Hospital, Guangxi Medical University, Nanning, China.

The Cochrane Database of Systematic Reviews
|October 19, 2012
PubMed
Summary
This summary is machine-generated.

Pregabalin showed inferior efficacy compared to lamotrigine for newly diagnosed partial seizures, with similar tolerability but more adverse events. Data were insufficient to compare pregabalin with gabapentin, necessitating further research.

More Related Videos

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Experiment Videos

Last Updated: May 17, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Epilepsy affects many individuals with poorly controlled seizures despite existing treatments.
  • High rates of treatment resistance drive interest in novel antiepileptic drugs like pregabalin.
  • The efficacy of pregabalin as monotherapy for epilepsy requires rigorous evaluation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of pregabalin as a monotherapy for epilepsy.
  • To compare pregabalin with placebo or other antiepileptic drugs in randomized controlled trials.

Main Methods:

  • Systematic search of multiple databases (Cochrane, MEDLINE, EMBASE, CBM) up to August 2012.
  • Inclusion of randomized controlled trials (RCTs) comparing pregabalin monotherapy with placebo or other antiepileptic drugs.
  • Extraction and quality assessment of trial data, focusing on seizure control, remission, withdrawal, quality of life, and adverse effects.

Main Results:

  • Two short-term studies (753 participants) met inclusion criteria, comparing pregabalin with lamotrigine or gabapentin.
  • Pregabalin demonstrated inferior efficacy to lamotrigine in seizure control and remission rates for partial seizures, with increased somnolence and weight gain.
  • Pregabalin showed better withdrawal outcomes than gabapentin, but study limitations and insufficient data preclude definitive conclusions.

Conclusions:

  • Pregabalin exhibits similar tolerability but inferior efficacy compared to lamotrigine for newly diagnosed partial seizures; results require cautious interpretation due to study limitations.
  • Limited data prevent conclusions on pregabalin versus gabapentin; regional differences in treatment effects were observed, particularly in Asia.
  • Further long-term trials are essential to ascertain the true effectiveness of pregabalin monotherapy, especially for generalized onset tonic-clonic seizures.